Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLO18H
|
|||
| Drug Name |
CB-103
|
|||
| Synonyms |
218457-67-1; 6-(4-tert-butylphenoxy)pyridin-3-amine; 5-Amino-2-(4-tert-butylphenoxy)pyridine; 6-(4-(tert-Butyl)phenoxy)pyridin-3-amine; 6-[4-(tert-butyl)phenoxy]pyridin-3-amine; UNII-Q5BB91JL0V; Q5BB91JL0V; MLS000833648; CB103; 6-(4-tert-butylphenoxy)-3-pyridinamine; SMR000457169; PubChem13390; Maybridge1_001148; Oprea1_231562; SCHEMBL4638726; CHEMBL1420319; BDBM87327; cid_2735289; GTPL10517; HMS544M04; DTXSID00370659; REGID_for_CID_2735289; HMS2787I06; ZINC152719; EX-A4302; MFCD00052647; NSC823659; s9719; SBB099607; AKOS000264357; CCG-233915; DB15279; NSC-823659; PS-7558; 5-Amino-2-(4-tertbutylphenoxy)pyridine; [6-(4-tert-butylphenoxy)-3-pyridyl]amine; 6-[4-(tert-butyl)phenoxy]-3-pyridylamine; DB-045711; HY-135145; CS-0109594; FT-0620888; 6-(4-(1,1-Dimethylethyl)phenoxy)-3-pyridinamine; A815692; 3-Pyridinamine, 6-(4-(1,1-dimethylethyl)phenoxy)-; 3-[(1H-PYRROLE-2-CARBONYL)-AMINO]PROPIONICACID
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 2 | [1] | |
| Company |
Cellestia
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H18N2O
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)OC2=NC=C(C=C2)N
|
|||
| InChI |
1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3
|
|||
| InChIKey |
WHIWGRCYMQLLAO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 218457-67-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04714619) CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.